Wave Life Sciences (NASDAQ:WVE) lost ~21% in the premarket on Wednesday after the company announced data from a Phase 1b/2a trial for its RNA-editing therapy WVE-006 developed with GSK (NYSE:GSK) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback